Pomerantz LLP Informs Shareholders of Securities Class Action Filing Against Telix Pharmaceuticals Limited – TLX

NEW YORK CITY, NY / ACCESS Newswire / December 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 9, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Telix securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

[Click here for information about joining the class action]

On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates."

On this news, Telix's American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.

Then, on August 28, 2025, Telix issued a press release "announcing that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), an investigational PET agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC)." Telix's press release stated, in relevant part: "The CRL identifies deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package. The FDA has requested additional data to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled-up manufacturing process intended for commercial use. Additionally, the FDA has documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission."

On this news, Telix's ADR price fell $3.45 per ADR, or 18.75%, to close at $14.95 per ADR on August 28, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 9, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Telix securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

[Click here for information about joining the class action]

On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates."

On this news, Telix's American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.

Then, on August 28, 2025, Telix issued a press release "announcing that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), an investigational PET agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC)." Telix's press release stated, in relevant part: "The CRL identifies deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package. The FDA has requested additional data to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled-up manufacturing process intended for commercial use. Additionally, the FDA has documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission."

On this news, Telix's ADR price fell $3.45 per ADR, or 18.75%, to close at $14.95 per ADR on August 28, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 9, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Telix securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

[Click here for information about joining the class action]

On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates."

On this news, Telix's American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.

Then, on August 28, 2025, Telix issued a press release "announcing that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), an investigational PET agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC)." Telix's press release stated, in relevant part: "The CRL identifies deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package. The FDA has requested additional data to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled-up manufacturing process intended for commercial use. Additionally, the FDA has documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission."

On this news, Telix's ADR price fell $3.45 per ADR, or 18.75%, to close at $14.95 per ADR on August 28, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / December 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 9, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Telix securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

[Click here for information about joining the class action]

On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates."

On this news, Telix's American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.

Then, on August 28, 2025, Telix issued a press release "announcing that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), an investigational PET agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC)." Telix's press release stated, in relevant part: "The CRL identifies deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package. The FDA has requested additional data to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled-up manufacturing process intended for commercial use. Additionally, the FDA has documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission."

On this news, Telix's ADR price fell $3.45 per ADR, or 18.75%, to close at $14.95 per ADR on August 28, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / December 5, 2025 / Levi & Korsinsky, LLP releases a Podcast regarding Telix Pharmaceuticals Ltd. class action securities lawsuit

A Class Action lawsuit was filed on behalf of Telix Pharmaceuticals Ltd. investors who lost money as a result of alleged securities fraud between February 21, 2025 and August 28, 2025.

Levi & Korsinsky has released a Podcast describing the nature of the action. The podcast for this class action lawsuit can be found here:

https://www.podbean.com/player-v2/?i=vpugv-19d35c4-pb&from=pb6admin&pbad=0&share=1&download=1&rtl=0&fonts=Arial&skin=1&font-color=&logo_link=episode_page&btn-skin=7

The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix's supply chain and partners; and (3) as a result, defendants' statements about Telix's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you have any questions about this class action lawsuit or any other sudden or unexpected stock loss, feel free to contact Levi & Korsinsky at (212)-363-7500.

You can also find recent podcasts regarding other class actions lawsuits and topics which are of interest to shareholders that have lost money in the stock market, here:

https://suewallst.podbean.com/

LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / December 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 9, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Telix securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

[Click here for information about joining the class action]

On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates."

On this news, Telix's American Depositary Receipt ("ADR") price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025.

Then, on August 28, 2025, Telix issued a press release "announcing that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), an investigational PET agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC)." Telix's press release stated, in relevant part: "The CRL identifies deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package. The FDA has requested additional data to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled-up manufacturing process intended for commercial use. Additionally, the FDA has documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission."

On this news, Telix's ADR price fell $3.45 per ADR, or 18.75%, to close at $14.95 per ADR on August 28, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP

View the original press release on ACCESS Newswire